F5A

2-[4-(4-chlorobenzene-1-carbonyl)phenoxy]-2-methylpropanoic acid

Created: 2019-01-23
Last modified:  2020-11-11

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count37
Chiral Atom Count0
Bond Count38
Aromatic Bond Count12
2D diagram of F5A
Toggle HydrogenToggle Labels

Chemical Component Summary

Name2-[4-(4-chlorobenzene-1-carbonyl)phenoxy]-2-methylpropanoic acid
Systematic Name (OpenEye OEToolkits)2-[4-(4-chlorophenyl)carbonylphenoxy]-2-methyl-propanoic acid
FormulaC17 H15 Cl O4
Molecular Weight318.752
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01C(C(=O)O)(C)(C)Oc1ccc(cc1)C(c2ccc(cc2)Cl)=O
SMILESCACTVS3.385CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(O)=O
SMILESOpenEye OEToolkits2.0.6CC(C)(C(=O)O)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl
Canonical SMILESCACTVS3.385 CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(O)=O
Canonical SMILESOpenEye OEToolkits2.0.6 CC(C)(C(=O)O)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl
InChIInChI1.03 InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
InChIKeyInChI1.03 MQOBSOSZFYZQOK-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB13873 
NameFenofibric acid
Groups approved
DescriptionFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362]
Synonyms
  • Fenofibric acid
  • Choline fenofibrate
Brand Names
  • Fibricor
  • Trilipix
  • Fenofibric acid
  • Fenofibric Acid
  • Fenofibric Acid Delayed-Release
IndicationFor use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). [FDA Label]
Categories
  • Acids, Acyclic
  • Agents Causing Muscle Toxicity
  • Anticholesteremic Agents
  • Benzene Derivatives
  • Benzophenones
ATC-CodeC10AB11
CAS number42017-89-0

Drug Targets

NameTarget SequencePharmacological ActionActions
Peroxisome proliferator-activated receptor alphaMVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFG...unknownagonist
Matrix metalloproteinase-25MRLRLRLLALLLLLLAPPARAPKPSAQDVSLGVDWLTRYGYLPPPHPAQA...unknownunknown
Peroxisome proliferator-activated receptor gammaMGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDL...unknown
Peroxisome proliferator-activated receptor deltaMEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSS...unknownunknown
Nuclear receptor subfamily 1 group I member 2MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG...unknownpartial agonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL981
PubChem 64929
ChEMBL CHEMBL981
ChEBI CHEBI:83469
CCDC/CSD QANHUJ
COD 2014749